Steven Cyr, MD, is a fellowship-trained spine surgeon who recently began providing stem cell treatments at SASpine in San Antonio.

Frank Phillips, MD, is the director of the section of minimally invasive spine surgery and director of the division of spine surgery at Chicago-based Rush University Medical Center.

Several clinical trials in China have been put on hold due to the coronavirus outbreak, including a treatment for a type of spondyloarthritis, according to Reuters.

This year marks the 15th anniversary of orthobiologic physician group Regenexx.

Onkos Surgical on Feb. 6 launched GenVie Magnesium Bone Scaffold, a magnesium-based bone void filler for orthopedic conditions.

Zolgensma, a gene therapy drug for spinal muscular atrophy, has been on the market since June 2019 and is widely reported to be the most expensive drug in the world.

Steven Cyr, MD, is now providing stem cell treatments at SASpine in San Antonio.

Myeliviz, a new drug to help diagnose multiple sclerosis in its earlier stages was recently approved by the FDA for human clinical trials.

Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, totaled $186 million in fourth quarter sales, according to Stat.

Here are eight things to know about the spinal fusion market.

In February, Ryan Woods, MD, will provide regenerative medicine services to patients at Orthopedics & Sports Medicine BayCare Clinic in Manitowoc, Wis., according to the Herald Times Reporter.

NanoFUSE Biologics appointed Answorth Allen, MD, Jan. 16 to its scientific advisory board, reports Benzinga.

The potential of spine-targeted biologics is immense and quickly developing. Here are four recent stories on notable developments or recognitions:

Stem Cells Translational Medicine recently awarded Mohamad Khazaei, PhD, its Young Investigator Award for his research on cell-based treatments for spinal cord injuries, reports News Medical Life Sciences.

Orthobiologic developer Bone Biologics said its rhNELL-1 product promoted bone formation in advanced spine models.

Developmental biologist Olivier Pourquié, PhD, identified a cellular segmentation clock-like mechanism in humans that controls spine development, The Harvard Gazette reports.

Ortho-biologics company Royal Biologics launched Magnus, a DMSO-free viable cellular bone allograft, the first of its kind to be DMSO-free.

NanoFUSE Biologics named Darren Lebl, MD, to its scientific advisory board.

Bioventus is partnering with Blue Cross Blue Shield of Michigan to provide its knee osteoarthritis treatments to Medicare Advantage and Commercial patients, beginning Jan. 1, 2020.

Here are nine key developments in stem cell research for spine this year: